SWOG clinical trial number
SWOG-8809

A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE- MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas

Closed
Phase
III
Accrual
100%
Published
Abbreviated Title
A Phase III Study of Alpha-Interferon Consolidation Following Intensive Chemotherapy with ProMACE- MOPP (Day 1-8) in Patients with Low Grade Malignant Lymphomas
Activated
10/01/1988
Closed
11/15/1994

Research committees

Lymphoma

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Survival by Hispanic Ethnicity Among Cancer Patients participating in SWOG Clinical Trials

A Moseley;M Chavez-MacGregor;J Unger;S Ramsey;D Hershman Society for Clinical Trials Annual Meeting (May 20-23 2018, Portland, OR), oral presentation

2012

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

D Persky;D Dornan;B Goldman;R Braziel;R Fisher;M LeBlanc;DG Maloney;OW Press;TP Miller;L Rimsza Haematologica 97(6):937-942

PMid: PMID22271896 | PMC number: PMC3366663

2010

Prognostic value of regulatory T-cells, lymphoma associated macrophages and Mum-11 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study [PMC2875547; PMID19875761]

JW Sweetenham;B Goldman;M LeBlanc;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;LM Rimsza;ED Hsi Annals of Oncology 21(6):1196-1202;

2009

Fc gamma receptor 3a genotype predicts overall survival for follicular lymphoma patients treated on Southwest Oncology Group trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone

DO Persky;D Dornan;B Goldman;M LeBlanc;RM Braziel;RI Fisher;D Maloney;T Miller;OW Press;LM Rimsza Blood 114:abst.#111 (ASH Annual Meeting, oral presentation)

2008

Non-hodgkins lymphoma

R Fisher;P Mauch;J Friedberg;L Rimsza In Cancer: Principles and Practice of Oncology, 8th edition, Lippincott, Williams & Wilkins, Baltimore, MD, pp 2098-2158, 2008

MUM1 expression in follicular lymphoma is a poor prognostic marker in patients treated with immunochemotherapy (SWOG 9800/9911) but not chemotherapy alone (SWOG 8809): A Southwest Oncology Group correlative science study

ED Hsi;B Goldman;LM Rimsza;JR Cook;RR Tubbs;OW Press;DG Maloney;RI Fisher;JW Sweetenham Blood 112(11):146, abst. 376

The Southwest Oncology Group: progress in cancer research [PMID18929152]

CA Coltman Seminars in Oncology 35(5):545-552

2007

Numbers of lymphoma associated macrophages (LAMS) and regulatory T-cells (Tregs) in follicular lymphoma (FL) patients (pts) treated with and without monoclonal antibody (MoAb)-containing therapy do not correlate with overall survival (OS): a study from the Southwest Oncology Group (SWOG)

JW Sweetenham;E Hsi;B Goldman;M LeBlanc;RR Tubbs;JR Cook;OW Press;RI Fisher;LM Rimsza Blood 110(11):#2602

2005

New treatment options have changed the survival of patients with follicular lymphoma

RI Fisher;M LeBlanc;OW Press;DG Maloney;JM Unger;TP Miller Journal of Clinical Oncology 23(33):8447-8452

2004

Follicular lymphoma international prognostic index

P Solal-Celigny;P Roy;P Colombat;J White;JO Armitage;R Arranz-Saez;WY Au;M Bellei;P Brice;D Caballero;D Coiffier;E Conde-Garcia;C Doyen;M Federico;RI Fisher;JF Garcia-Conde;C Gugliemi;A Hagenbeek;C Haioun;M LeBlanc;AT Lister;A Lopez-Guillermo;P McLaughlin;N Milpied;P Morel;N Mounier;SJ Proctor;A Rohatiner;P Smith;P Soubeyran;H Tilly;U Vitolo;PL Zinzani;E Zucca;E Montserrat Blood 104(5):1258-1265

2000

Interferon alfa consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low -grade non-hodgkin's lymphoma: results of theSouthwest Oncology Group randomized phase III study 8809

RI Fisher;BW Dana;M LeBlanc;C Kjeldsberg;JD Forman;JM Unger;SP Balcerzak;ER Gaynor;V Roy;T Miller Journal of Clinical Oncology 18(10):2010-2016

1998

A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809).

BW Dana;J Unger;RI Fisher Proc of the American Society of Clinical Oncology 17:3a(#10)

A randomized study of alpha-interferon consolidation in patients with low-grade lymphoma who have responded to pro-MACE-MOPP (day 1-8) (SWOG 8809).

RI Fisher;J Unger;BW Dana Annals of Hematology 77(Suppl.1):A9(#36)

Other Clinical Trials

SWOG Clinical Trial Number
SWOG-7204/7205

Non-Hodgkin's Lymphoma CHOP vs. HOP Combination Chemotherapy for Remission Induction and COP vs. OAP Combination Chemotherapy for Maintenance

Research Committee(s)
Lymphoma
Activated
04/17/1972
Closed
09/10/1974
Closed
Phase
III
Published
SWOG Clinical Trial Number
SWOG-7426/7427
SWOG Clinical Trial Number
SWOG-7713/14